Stock Detail
NPS PHARMACEUTICALS INC
Drugs
NPSP @ Yahoo Finance | NPSP Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $5.54 | $5.76 | $-0.13 | -2.29% | 0.00 | $5.67 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $5.61 | $5.51 | 827,399 | 476.89M | 1.36M | -12.59 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 5.85 | 5.69 | 5.60 | 5.44 | 5.35 |
Stock Profile
NPS Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company's product candidates are used primarily for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. NPS's products include PREOS, Calcilytic Compounds, Cinacalcet HCl, Teduglutide, mGluR5 Antagonists, Isovaleramide, Delucemine, Metabotropic Glutamate Receptors, and Glycine Reuptake Inhibitors. The PREOS and Calcilytic Compounds are in phase III and I stage respectively, which are used for the treatment of osteoporosis. The Cinacalcet HCl is in phase II stage, which is used for Hyperparathyroidism. The Teduglutide is in phase II stage and is used for short bowel syndrome or crohn's disease. The mGluR5 Antagonists is in the preclinical stage, which is for gastroesophageal reflux disease. The Isovaleramide is in phase II stage and is used for migraine. The Delucemine is in phase I stage that is used for depression. The Metabotropic Glutamate Receptors is in preclinical stage, which is used for psychiatric and neurologic disorders and pain. The Glycine Reuptake Inhibitors is in preclinical stage that is used for schizophrenia and dementia. The company has collaborative research, development, or license agreements with Amgen, Inc.; AstraZeneca AB; Janssen Pharmaceutical N.V; GlaxoSmithKline; Kirin Brewery, Ltd.; and Nycomed Danmark ApS. The company was founded in 1986 and is headquartered in Salt Lake City, Utah.